London, UK, Boston, US, June 14, 2012 - IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced that the University of Cape Town (UCT) Drug Discovery and Development Centre, H3-D (http://www.h3-d.uct.ac.za/), is using the BioBook Electronic Laboratory Notebook (ELN) to store, manage and analyze its Drug Metabolism and Pharmacokinetic (DMPK) data. Aligning itself with international standards in drug discovery, H3-D benefits from BioBook’s ability to consolidate assay results in one place, improving workflow and accelerating preclinical research.
“BioBook helps us undertake world class research from right here in South Africa. It is an exciting step for us as we are not only working faster but we are doing so without compromising on quality. Our confidence in our data continues to grow every day,” said Dr Nyaradzo T.L Chigorimbo-Tsikiwa, a postdoctoral fellow within H3-D. “Having worked with BioBook previously, I’m confident in its abilities to provide us with the efficiency and traceability that we require in our fast moving environment.”
BioBook is currently being rolled out across H3-D. Users are able to track research projects and manage the large volumes of data associated with individual assays. Analysis is completed within the system rather than relying on Microsoft Excel for data handling. Working in this efficient way minimizes the risk of human error and enables H3-D to advance it’s drug discovery on a global scale with conviction in its research findings.
Neil Kipling, CEO and Founder of IDBS said, “The world’s leading academic institutions are now taking advantage of industrial informatics platforms like BioBook. Our ELN significantly improves workflow and boosts research productivity by up to 30%. It also makes collaboration easier and enables better decision making. This new relationship with UCT demonstrates our commitment to providing global academia with modern informatics technologies which can revolutionize academic R&D.”
BioBook is a flexible, automated solution which dramatically reduces time to market in late stage discovery, pharmacology and preclinical R&D. It integrates with legacy data software such as laboratory information management systems (LIMS) and combines data imported from laboratory instruments to keep all research in one secure environment.
For further press information please contact:
Metia for IDBS
IDBS@Metia.com
+44 (0)20 3100 3796
About IDBS
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, high-tech materials and consumer products, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.
